Reuters Health Report

Click to View in Browser 04/7/2014 Roche buys rights to Oryzon's cancer-suppressing gene drug ZURICH (Reuters) - Roche has bought the rights to an experimental drug from Spain's Oryzon Genomics that can switch on genes to block cancer growth, as the Swiss drugmaker looks to maintain its dominance in the lucrative field of oncology. Puma drug better than Herceptin in HER2 breast cancers: trial (Reuters) - A mid-stage trial of Puma Biotechnology's experimental drug neratinib showed that it was more effective, given before surgery, than Herceptin, the Roche drug commonly used in women with a type of breast cancer fueled by a protein called HER2. Fatal virus in Ghana tests negative for Ebola ACCRA (Reuters) - Blood tests have shown that a 12-year-old girl in Ghana who died of viral fever with bleeding did not have Ebola, Health Minister Sherry Ayittey said on Monday. MannKind says FDA delays decision on inhaled insulin treatment (Reuters) - MannKind Corp said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months, sending the company's shares down as much as 22 percent before the bell. Novartis' meningitis B vaccine wins breakthrough therapy status in U.S. ZURICH (Reuters) - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status. Drugmaker GSK investigates alleged bribery in Iraq LONDON (Reuters) - Drugmaker GlaxoSmithKline, already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the British company said on Sunday. Mallinckrodt to buy Questcor for its lucrative MS drug (Reuters) - Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel. Pfizer drug doubles time to breast cancer tumor growth in trial (Reuters) - Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. Agios leukemia drug shows promise in tiny, early study (Reuters) - An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday. Exclusive: Nestle and Fresenius home in on Danone Medical - sources LONDON/FRANKFURT (Reuters) - The field of bidders for Danone's Medical Nutrition business has narrowed to German healthcare group Fresenius and Swiss food company Nestle, two people familiar with the process told Reuters on Friday. Related Video Radiation belt a new line of defence in nuclear emergency Car-to-car warning system set for America's roads The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend